Trial Number

015-20

Age range

18 years and younger

Gender

Male or Female

Enrolling Patients

Yes

A substantial portion of intracerebral hemorrhage (ICH) survivors have atrial fibrillation/flutter (AF) and are at high risk for subsequent ischemic stroke. Although randomized clinical trials have established theeffectiveness of anticoagulant therapy for preventing ischemic stroke in patients with AF, these trials did not enroll ICH patients because of concern that a potential increase in risk for recurrent hemorrhagic strokes would offset any benefit. The Anticoagulation in Intracerebral Hemorrhage Survivors for Stroke Prevention and Recovery (ASPIRE) study is a randomized, double-blinded, phase III clinical trial designed to test the efficacy and safety of anticoagulation, compared with aspirin, in patients with a recent ICH and high-risk nonvalvular AF.

Principal Investigator

MemorialCare Research Center Contact Form

For further information about this study or to express your interest in this study, please fill out and submit this form.

Name
Address
Enter Trial number from the area just below the marquee.
How would you prefer to be contacted?
How did you hear about us?
This registration is for:
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.